Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus UNASYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus UNASYN.
KLEBCIL vs UNASYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic